Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
National multicenter real‑world phase IV trial of linperlisib in indolent B‑cell lymphoma
CTR20241850Phase 4Active
- Sponsor
- Yingli Pharma
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of linperlisib in low-grade B-cell lymphoma, follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone B-cell lymphoma (MZL), Lymphoplasmacytic Lymphoma (LPL), sponsored by Yingli Pharma. Started Jun 2024; status: active.
02
Drugs
linperlisib
03
Conditions
low-grade B-cell lymphomafollicular lymphoma (FL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)marginal zone B-cell lymphoma (MZL)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on CTR20241850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241850.